Last reviewed · How we verify

HIT-SKK Chemotherapy Cycles B1-3

Nationwide Children's Hospital · Phase 3 active Small molecule

HIT-SKK Chemotherapy Cycles B1-3 is a Polychemotherapy regimen Small molecule drug developed by Nationwide Children's Hospital. It is currently in Phase 3 development for Pediatric acute lymphoblastic leukemia (ALL), Pediatric non-Hodgkin lymphoma.

HIT-SKK is a multi-agent chemotherapy regimen combining doxorubicin, cyclophosphamide, etoposide, and other agents designed to treat pediatric hematologic malignancies through DNA damage and cell cycle disruption.

HIT-SKK is a multi-agent chemotherapy regimen combining doxorubicin, cyclophosphamide, etoposide, and other agents designed to treat pediatric hematologic malignancies through DNA damage and cell cycle disruption. Used for Pediatric acute lymphoblastic leukemia (ALL), Pediatric non-Hodgkin lymphoma.

At a glance

Generic nameHIT-SKK Chemotherapy Cycles B1-3
SponsorNationwide Children's Hospital
Drug classPolychemotherapy regimen
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

HIT-SKK (Hämato-Immunologische Therapie) is a complex polychemotherapy protocol used primarily in pediatric acute lymphoblastic leukemia (ALL) and other hematologic malignancies. The regimen employs multiple chemotherapy agents with different mechanisms—including topoisomerase inhibitors, alkylating agents, and anthracyclines—to maximize tumor cell kill through complementary pathways while managing resistance development.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about HIT-SKK Chemotherapy Cycles B1-3

What is HIT-SKK Chemotherapy Cycles B1-3?

HIT-SKK Chemotherapy Cycles B1-3 is a Polychemotherapy regimen drug developed by Nationwide Children's Hospital, indicated for Pediatric acute lymphoblastic leukemia (ALL), Pediatric non-Hodgkin lymphoma.

How does HIT-SKK Chemotherapy Cycles B1-3 work?

HIT-SKK is a multi-agent chemotherapy regimen combining doxorubicin, cyclophosphamide, etoposide, and other agents designed to treat pediatric hematologic malignancies through DNA damage and cell cycle disruption.

What is HIT-SKK Chemotherapy Cycles B1-3 used for?

HIT-SKK Chemotherapy Cycles B1-3 is indicated for Pediatric acute lymphoblastic leukemia (ALL), Pediatric non-Hodgkin lymphoma.

Who makes HIT-SKK Chemotherapy Cycles B1-3?

HIT-SKK Chemotherapy Cycles B1-3 is developed by Nationwide Children's Hospital (see full Nationwide Children's Hospital pipeline at /company/nationwide-children-s-hospital).

What drug class is HIT-SKK Chemotherapy Cycles B1-3 in?

HIT-SKK Chemotherapy Cycles B1-3 belongs to the Polychemotherapy regimen class. See all Polychemotherapy regimen drugs at /class/polychemotherapy-regimen.

What development phase is HIT-SKK Chemotherapy Cycles B1-3 in?

HIT-SKK Chemotherapy Cycles B1-3 is in Phase 3.

What are the side effects of HIT-SKK Chemotherapy Cycles B1-3?

Common side effects of HIT-SKK Chemotherapy Cycles B1-3 include Myelosuppression, Nausea and vomiting, Alopecia, Mucositis, Cardiotoxicity, Infection.

Related